Bifunctional cancer cell–based vaccine concomitantly drives direct tumor killing and antitumor immunity
- 4 January 2023
- journal article
- research article
- Published by American Association for the Advancement of Science (AAAS) in Science Translational Medicine
- Vol. 15 (677) , eabo4778
Abstract
The administration of inactivated tumor cells is known to induce a potent antitumor immune response; however, the efficacy of such an approach is limited by its inability to kill tumor cells before inducing the immune responses. Unlike inactivated tumor cells, living tumor cells have the ability to track and target tumors. Here, we developed a bifunctional whole cancer cell–based therapeutic with direct tumor killing and immunostimulatory roles. We repurposed the tumor cells from interferon-β (IFN-β) sensitive to resistant using CRISPR-Cas9 by knocking out the IFN-β–specific receptor and subsequently engineered them to release immunomodulatory agents IFN-β and granulocyte-macrophage colony-stimulating factor. These engineered therapeutic tumor cells (ThTCs) eliminated established glioblastoma tumors in mice by inducing caspase-mediated cancer cell apoptosis, down-regulating cancer-associated fibroblast-expressed platelet-derived growth factor receptor β, and activating antitumor immune cell trafficking and antigen-specific T cell activation signaling. This mechanism-based efficacy of ThTCs translated into a survival benefit and long-term immunity in primary, recurrent, and metastatic cancer models in immunocompetent and humanized mice. The incorporation of a double kill-switch comprising herpes simplex virus–1 thymidine kinase and rapamycin-activated caspase 9 in ThTCs ensured the safety of our approach. Arming naturally neoantigen-rich tumor cells with bifunctional therapeutics represents a promising cell-based immunotherapy for solid tumors and establishes a road map toward clinical translation.Keywords
This publication has 76 references indexed in Scilit:
- Therapeutic Effect of Human iPS-Cell–Derived Myeloid Cells Expressing IFN-β against Peritoneally Disseminated Cancer in Xenograft ModelsPLOS ONE, 2013
- Induction of tumoricidal function in CD4+ T cells is associated with concomitant memory and terminally differentiated phenotypeJournal of Experimental Medicine, 2012
- Platelet-derived growth factor receptors differentially inform intertumoral and intratumoral heterogeneityGenes & Development, 2012
- Neutrophils responsive to endogenous IFN-β regulate tumor angiogenesis and growth in a mouse tumor modelJournal of Clinical Investigation, 2010
- Naive tumor-specific CD4+ T cells differentiated in vivo eradicate established melanomaJournal of Experimental Medicine, 2010
- Tumor-reactive CD4+ T cells develop cytotoxic activity and eradicate large established melanoma after transfer into lymphopenic hostsJournal of Experimental Medicine, 2010
- Tumor Self-Seeding by Circulating Cancer CellsCell, 2009
- Bimodal Viral Vectors andIn VivoImaging Reveal the Fate of Human Neural Stem Cells in Experimental Glioma ModelJournal of Neuroscience, 2008
- Alternative Signaling Pathways Regulating Type I Interferon-Induced ApoptosisJournal of Interferon & Cytokine Research, 2005
- “Of mice and men”European Journal of Cancer, 2004